Why this site exists

The short version

I'm Colin. I'm 5'11" and I started this at 100kg. That put me squarely in the "obese" band on the BMI chart, which is a word you tend to avoid using about yourself right up until a number on a chart uses it for you.

I spent weeks researching before I did anything. Not a weekend of skim-reading — weeks. Trial data, dosing protocols, supplier reputations, UK legal status, what the kit costs, what could go wrong. By the end of it I had a folder of notes that I realised was more useful and more honest than anything I'd been able to find online when I started.

So I decided to publish it, and to keep publishing as I go.

What I'm actually taking

I'm using Retatrutide — a triple-agonist compound developed by Eli Lilly that hits GLP-1, GIP and glucagon receptors simultaneously. It is not licensed in the UK. It is not available on the NHS or by private prescription. I'm accessing it through the research peptide route, which is legal but entirely unregulated, and I'm not going to pretend that's a small detail.

I chose it because the clinical data is, frankly, remarkable. I'm documenting it because the gap between that data and what an ordinary person in the UK can actually find out is enormous.

Why publish it?

Three reasons.

One: everything else out there is selling you something. Search any of these drug names and you'll get clinic landing pages, subscription funnels, and content written by people who have never held a vial. The genuinely useful information — what it costs in pounds, what to buy, what week three feels like — is scattered across forum posts and Reddit threads, mostly American, mostly out of date.

Two: accountability. It is considerably harder to quietly give up on something when you've told the internet you're doing it and you've promised to post the numbers every week. That's not incidental — that's part of why I'm doing it this way.

Three: if it doesn't work, that's worth publishing too. There is a strong selection bias in this space: the people who succeed write it up, and the people who don't go quiet. I'm committing now, in writing, to posting the bad weeks, the plateaus, the side effects and the point where I want to pack it in. If this fails, you'll read about it here.

What I'm not

I'm one person, with one body, taking one compound, and reporting what happens. That's a case study with a sample size of one. It is not evidence, and I'd ask you not to treat it as such.

How this site makes money

I'd rather tell you plainly than have you work it out.

Some links to equipment — pens, needles, bacteriostatic water, sharps bins — are Amazon affiliate links. If you buy through one, I earn a small commission at no extra cost to you. There are also referral links to UK clinics that prescribe licensed GLP-1 medications, which pay me if you sign up. In time, when the site has enough readers to justify it, there may be display advertising.

What that money doesn't buy is my opinion. I'm not paid by any drug company, clinic or peptide supplier to say anything, and if I think a product is a waste of money I'll say so and leave the commission on the table. Every affiliate link on this site points to something I have actually bought and used.

Get in touch

If you're on a similar path, spot an error, or think I've got something wrong — I want to hear it. The quickest way to follow along is the weekly email below.